Human XL Cytokine Luminex® Performance Assay 44-plex Fixed Panel
Discontinued Product
LKTM014 has been discontinued and is replaced by LKTM014B.
U.S. orders usually ship in 1-2 business days
Human XL Cytokine Luminex® Performance Assay 44-plex Fixed Panel Summary
| Assay Type | bead-based multiplex assay for the Luminex® platform |
| Format | 1 x 96-well microplate and antibody-coated beads |
| Analytes Detected | Please see analyte list in assay customization tool below. |
| Performance Validation | Luminex Assays are validated for use with cell culture supernatants, plasma and serum. All Luminex assays are tested for sensitivity, intra-assay precision, inter-assay precision and to ensure assay linearity for validated sample types. Antibody pairs are selected and tested to confirm the parallel detection of natural and recombinant standard protein and to ensure the accurate determination of target analytes within biological samples. Assays for each target analyte are screened against all target analytes to confirm low antibody cross-reactivity. View Luminex High Performance Human XL validation data. |
Not finding your analyte of interest? View our complete Luminex offering in the full version of our Luminex Assay Customization Tool. We also offer Custom Luminex Services.
Precision
|
Intra-Assay Precision - is generated from the mean of the %CV's from 40 reportable results across two different concentrations of analytes in a single serum assay Inter-Assay Precision - is generated from the mean of the %CV's across two different concentrations of analytes across 25 different serum assays. |
||
| n=40 (20x2 levels) | n=25 | |
|---|---|---|
| Analyte | Intra-Assay (%CV) | Inter-Assay (%CV) |
| B7-H1/PD-L1 | 1.8% | 11.3% |
| CCL11/Eotaxin | 3.2% | 10.0% |
| CCL19/MIP-3beta | 2.2% | 9.7% |
| CCL2/MCP-1 | 1.4% | 8.9% |
| CCL20/MIP-3 alpha | 2.4% | 9.9% |
| CCL3/MIP-1alpha | 1.5% | 7.3% |
| CCL4/MIP-1beta | 3.0% | 9.6% |
| CD40 Ligand | 3.3% | 10.6% |
| CXCL1/GRO alpha | 1.0% | 8.0% |
| CXCL10/IP-10 | 2.1% | 8.8% |
| CXCL2/GRO beta | 1.2% | 8.8% |
| CXCL8/IL-8 | 1.8% | 9.0% |
| EGF | 3.0% | 9.6% |
| FGF-basic | 4.2% | 12.6% |
| Flt-3 ligand | 2.5% | 10.1% |
| G-CSF | 1.8% | 10.2% |
| GM-CSF | 3.1% | 10.3% |
| Granzyme B | 1.8% | 11.0% |
| IFN-alpha | 2.9% | 9.9% |
| IFN-beta | 3.0% | 11.0% |
| IFN-gamma | 2.8% | 10.4% |
| IL-10 | 3.3% | 9.0% |
| IL-12 p70 | 2.3% | 10.5% |
| IL-13 | 1.6% | 9.7% |
| IL-15 | 2.4% | 9.9% |
| IL-17A | 2.5% | 11.2% |
| IL-17E/IL-25 | 1.7% | 9.2% |
| IL-1alpha | 3.0% | 10.4% |
| IL-1beta | 2.3% | 10.0% |
| IL-1ra | 2.1% | 10.3% |
| IL-2 | 2.2% | 9.2% |
| IL-3 | 2.5% | 10.1% |
| IL-33 | 2.4% | 12.3% |
| IL-4 | 3.2% | 9.7% |
| IL-5 | 2.2% | 12.0% |
| IL-6 | 2.6% | 9.8% |
| IL-7 | 2.5% | 9.8% |
| PDGF-AA | 2.8% | 15.5% |
| PDGF-AB/BB | 2.4% | 12.4% |
| RANTES | 4.7% | 17.4% |
| TGF-alpha | 3.0% | 9.8% |
| TNF-alpha | 2.2% | 8.7% |
| TRAIL | 2.0% | 10.3% |
| VEGF | 2.6% | 10.3% |
Accuracy
|
Linearity - The data represents mean spiked or natural linearity in serum matrix samples. Samples with natural linearity are marked with an astrisk. Spike Recovery - The data represents mean percent recovery of spiked standards ranging from low, medium, and high concentration in serum matrix samples. |
||||
| Linearity | Spiked Recovery |
|||
|---|---|---|---|---|
| Analyte | N | Average % | N | Average % |
|
*Natural linearity |
||||
| B7-H1/PD-L1 | 4 | 106% | 4 | 109% |
| CCL11/Eotaxin | 4 | 92% | 4 | 107% |
| CCL19/MIP-3beta | 4 | 123% | 4 | 95% |
| CCL2/MCP-1 | 4* | 82% | High endogenous | |
| CCL20/MIP-3 alpha | 4 | 107% | 4 | 99% |
| CCL3/MIP-1alpha | 4 | 77% | 4 | 139% |
| CCL4/MIP-1beta | 4 | 103% | 4 | 111% |
| CD40 Ligand | 4 | 113% | 4 | 100% |
| CXCL1/GRO alpha | 4 | 80% | High endogenous | |
| CXCL10/IP-10 | 3 | 110% | High endogenous | |
| CXCL2/GRO beta | 4* | 114% | 3 | 106% |
| CXCL8/IL-8 | 4 | 118% | 4 | 96% |
| EGF | 4* | 110% | 4 | 106% |
| FGF-basic | 4 | 161% | 3 | 80% |
| Flt-3 ligand | 4 | 102% | 4 | 109% |
| G-CSF | 4 | 209% | 4 | 43% |
| GM-CSF | 4 | 96% | 4 | 110% |
| Granzyme B | 4 | 99% | 4 | 118% |
| IFN-alpha | 3 | 98% | 4 | 101% |
| IFN-beta | 4 | 148% | 4 | 69% |
| IFN-gamma | 4 | 97% | 4 | 112% |
| IL-10 | 4 | 111% | 4 | 104% |
| IL-12 p70 | 4 | 106% | 4 | 108% |
| IL-13 | 4 | 112% | 4 | 103% |
| IL-15 | 3 | 88% | 3 | 89% |
| IL-17A | 4 | 110% | 4 | 106% |
| IL-17E/IL-25 | 4 | 122% | 4 | 87% |
| IL-1alpha | 4 | 143% | 4 | 80% |
| IL-1beta | 4 | 107% | 4 | 99% |
| IL-1ra | 4* | 100% | 4 | 145% |
| IL-2 | 4 | 105% | 4 | 102% |
| IL-3 | 4 | 123% | 4 | 88% |
| IL-33 | 4 | 93% | 4 | 110% |
| IL-4 | 3 | 127% | 3 | 77% |
| IL-5 | 3 | 113% | 3 | 81% |
| IL-6 | 3 | 124% | 3 | 90% |
| IL-7 | 4 | 113% | 4 | 96% |
| PDGF-AA | 4* | 90% | High endogenous | |
| PDGF-AB/BB | 4* | 96% | High endogenous | |
| RANTES | 4* | 96% | High endogenous | |
| TGF-alpha | 4 | 117% | 4 | 96% |
| TNF-alpha | 4 | 117% | 4 | 69% |
| TRAIL | 3 | 123% | 4 | 88% |
| VEGF | 4 | 103% | 4 | 109% |
Assays for the Luminex platform are offered as High Performance Assays or Assays. The Luminex High Performance Assays are fully validated panels with a focused selection of analytes. They are available in We Mix, You Mix, and Predetermined formats. The Luminex Assays allows for the maximum number of analytes in a multiplex and is supplied as a premixed kit. View a table comparing the features and benefits of these bead-based multiplex assays.
Scientific Data
View Larger
Human XL Cytokine Performance Luminex Panel Serum Sample Values Serum samples from 20 apparently healthy individuals were run on the Human XL Cytokine Luminex High Performance Panel and sample values plotted. Minimum and maximum values shown by exterior lines, the box represents the 1st and 3rd quartiles with the center line representing the median.
Product Datasheets
Citations for Human XL Cytokine Luminex® Performance Assay 44-plex Fixed Panel
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
12
Citations: Showing 1 - 10
Filter your results:
Filter by:
-
Higher levels of IL-1ra, IL-6, IL-8, MCP-1, MIP-3?, MIP-3?, and fractalkine are associated with 90-day mortality in 132 non-immunomodulated hospitalized patients with COVID-19
Authors: Rabøl Andersen, L;Hindsberger, B;Bastrup Israelsen, S;Pedersen, L;Bela Szecsi, P;Benfield, T;
PloS one
Species: Human
Sample Types: Serum
-
Anti-Tumor Immunogenicity of the Oncolytic Virus CF33-hNIS-antiPDL1 against Ex Vivo Peritoneal Cells from Gastric Cancer Patients
Authors: Zhang, Z;Yang, A;Chaurasiya, S;Park, AK;Kim, SI;Lu, J;Valencia, H;Fong, Y;Woo, Y;
International journal of molecular sciences
Species: Human
Sample Types: Cell Culture Supernates
-
Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma
Authors: Naghavian, R;Faigle, W;Oldrati, P;Wang, J;Toussaint, NC;Qiu, Y;Medici, G;Wacker, M;Freudenmann, LK;Bont�, PE;Weller, M;Regli, L;Amigorena, S;Rammensee, HG;Walz, JS;Brugger, SD;Mohme, M;Zhao, Y;Sospedra, M;Neidert, MC;Martin, R;
Nature
Species: Human
Sample Types: Cell Culture Supernates
-
Tissue CD14+CD8+ T cells reprogrammed by myeloid cells and modulated by LPS
Authors: LJ Pallett, L Swadling, M Diniz, AA Maini, M Schwabenla, AD Gasull, J Davies, S Kucykowicz, JK Skelton, N Thomas, NM Schmidt, OE Amin, US Gill, KA Stegmann, AR Burton, E Stephenson, G Reynolds, M Whelan, J Sanchez, R de Maeyer, C Thakker, K Suveizdyte, I Uddin, AM Ortega-Pri, C Grant, F Froghi, G Fusai, S Lens, S Pérez-Del-, W Al-Akkad, G Mazza, M Noursadegh, A Akbar, PTF Kennedy, BR Davidson, M Prinz, BM Chain, M Haniffa, DW Gilroy, M Dorner, B Bengsch, A Schurich, MK Maini
Nature, 2023-01-25;614(7947):334-342.
Species: Human
Sample Types: Cell Culture Supernates
-
The Characteristics of Microbiome and Cytokines in Healthy Implants and Peri-Implantitis of the Same Individuals
Authors: L Song, J Jiang, J Li, C Zhou, Y Chen, H Lu, F He
Journal of Clinical Medicine, 2022-09-30;11(19):.
Species: Human
Sample Types: Cell Culture Supernates
-
Systemic Immune Dysfunction in Cancer Patients Driven by IL6 Induction of LAG3 in Peripheral CD8+ T Cells.
Authors: Somasundaram A, Cillo A, Lampenfeld C, Workman C, Kunning S, Oliveri L, Velez M, Joyce S, Calderon M, Dadey R, Rajasundaram D, Normolle D, Watkins S, Herman J, Kirkwood J, Lipson E, Ferris R, Bruno T, Vignali D
Cancer Immunol Res, 2022-07-01;10(7):885-899.
Species: Human
Sample Types: Whole Cells
-
Targeting human Acyl-CoA:cholesterol acyltransferase as a dual viral and T�cell metabolic checkpoint
Authors: NM Schmidt, PAC Wing, MO Diniz, LJ Pallett, L Swadling, JM Harris, AR Burton, A Jeffery-Sm, N Zakeri, OE Amin, S Kucykowicz, MH Heemskerk, B Davidson, T Meyer, J Grove, HJ Stauss, I Pineda-Tor, C Jolly, EC Jury, JA McKeating, MK Maini
Nature Communications, 2021-05-14;12(1):2814.
Species: Human
Sample Types: Cell Culture Supernates
-
Plasma biomarker profiling of PIMS-TS, COVID-19 and SARS-CoV2 seropositive children - a cross-sectional observational study from southern India
Authors: A Venkataram, NP Kumar, LE Hanna, S Putlibai, M Karthick, A Rajamanika, K Sadasivam, B Sundaram, S Babu
EBioMedicine, 2021-04-02;66(0):103317.
Species: Human
Sample Types: Plasma
-
The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome
Authors: M Blot, JB Bour, JP Quenot, A Bourredjem, M Nguyen, J Guy, S Monier, M Georges, A Large, A Dargent, A Guilhem, S Mouries-Ma, J Barben, B Bouhemad, PE Charles, P Chavanet, C Binquet, L Piroth, LYMPHONIE
Journal of Translational Medicine, 2020-12-03;18(1):457.
Species: Human
Sample Types: Plasma
-
CXCL10 could drive longer duration of mechanical ventilation during COVID-19 ARDS
Authors: M Blot, M Jacquier, LS Aho Glele, G Beltramo, M Nguyen, P Bonniaud, S Prin, P Andreu, B Bouhemad, JB Bour, C Binquet, L Piroth, JP Pais de Ba, D Masson, JP Quenot, PE Charles, Pneumochon
Crit Care, 2020-11-02;24(1):632.
Species: Human
Sample Types: BALF
-
Cytokine profiling of extracellular vesicles isolated from plasma in myalgic encephalomyelitis/chronic fatigue syndrome: a pilot study
Authors: L Giloteaux, A O'Neal, J Castro-Mar, SM Levine, MR Hanson
J Transl Med, 2020-10-12;18(1):387.
Species: Human
Sample Types: Plasma
-
Higher plasma levels of Chemokine CCL19 are associated with poor SARS-CoV-2 acute respiratory distress syndrome (ARDS) outcomes
Authors: J Balnis, AP Adam, A Chopra, HC Chieng, PJ Feustel, KA Overmyer, E Shishkova, JC Coon, HA Singer, MA Judson, A Jaitovich
medRxiv, 2020-08-18;0(0):.
Species: Human
Sample Types: Plasma
FAQs
No product specific FAQs exist for this product, however you may
View all Luminex Assay FAQsReviews for Human XL Cytokine Luminex® Performance Assay 44-plex Fixed Panel
Average Rating: 5 (Based on 1 Review)
Have you used Human XL Cytokine Luminex® Performance Assay 44-plex Fixed Panel?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
The human XL Cytokine fixed panel performed as expected with low % CV's for all analytes
